Back to Search Results
Back to Results
Breast
General Information
Study Name:
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004)
Age Group:
Adult
Protocol Number:
NCT03199885
Background Information:
The purpose of this study is to help determine if HER-2 positive, metastatic breast cancer can be stabilized and life with the disease be extended by adding a new drug to the standard treatment regimen
Offered at:
Inova Schar Cancer Institute
A department of Inova Fairfax Hospital
8081 Innovation Park Drive
Fairfax, VA 22031
And:
Inova Schar Cancer Institute
3580 Joseph Siewick Drive, Suite 403
Fairfax, VA 22033
Eligibility Information
Male or female over 18 years of age
Documented classification of HER-2 positive, metastatic breast cancer
Adequate hematologic, hepatic, and renal function
Additional eligibility in protocol
Ineligibility Information
Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases (some exceptions detailed in protocol)
Known leptomeningeal carcinomatosis
History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to randomization
Active cardiac disease
History of systemic anti-cancer therapies (specific exclusions in protocol)
Patients with clinically active tuberculosis
Additional ineligibility in protocol
Contact Information
Contact Name:
Hunfa Asghar
Contact Phone:
571-472-0626
Contact Email:
hunfa.asghar@inova.org
For more information go to
https://clinicaltrials.gov/ct2/show/NCT03199885